Abstract | PURPOSE OF REVIEW: Although there are extensive studies of postoperative and postdischarge nausea and vomiting ( PONV/PDNV) up to 24 h, few investigate 'delayed PDNV'. With an increasing outpatient surgical population, specific 'delayed PDNV' risk identification and management is necessary for improving outcomes and helping patients after discharge. This review will discuss possible PDNV specific risk factors, successful prevention and management of PDNV following ambulatory anesthesia and the principles and pharmacology of these interventions. RECENT FINDINGS: Current research has demonstrated beneficial PDNV management up to 72 h with the long-acting 5-hydroxytryptamine-3 receptor antagonist palonosetron. Neurokinin-1 antagonists have demonstrated superior antiemesis, but not antinausea compared with more traditional and less expensive options. Dexamethasone provides improvements in quality of recovery associated with improved PDNV outcomes. SUMMARY:
|
Authors | M Stephen Melton, Stephen M Klein, Tong J Gan |
Journal | Current opinion in anaesthesiology
(Curr Opin Anaesthesiol)
Vol. 24
Issue 6
Pg. 612-9
(Dec 2011)
ISSN: 1473-6500 [Electronic] United States |
PMID | 21934496
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antiemetics
- Cholinergic Antagonists
- Glucocorticoids
- Isoquinolines
- Neurokinin-1 Receptor Antagonists
- Quinuclidines
- Serotonin Antagonists
- Palonosetron
- Dexamethasone
|
Topics |
- Ambulatory Surgical Procedures
- Anesthesia
(adverse effects)
- Antiemetics
(therapeutic use)
- Cholinergic Antagonists
(therapeutic use)
- Combined Modality Therapy
- Dexamethasone
(therapeutic use)
- Glucocorticoids
(therapeutic use)
- Humans
- Isoquinolines
(therapeutic use)
- Neurokinin-1 Receptor Antagonists
- Palonosetron
- Patient Discharge
- Postoperative Nausea and Vomiting
(drug therapy, prevention & control)
- Quinuclidines
(therapeutic use)
- Risk Factors
- Serotonin Antagonists
(therapeutic use)
|